

# Celalettin Ustun

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/907604/publications.pdf>

Version: 2024-02-01

215  
papers

7,074  
citations

76326

40  
h-index

69250

77  
g-index

218  
all docs

218  
docs citations

218  
times ranked

8683  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML. <i>New England Journal of Medicine</i> , 2019, 381, 1728-1740.	27.0	796
2	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1/2 study. <i>Lancet Oncology</i> , 2017, 18, 1061-1075.	10.7	402
3	Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. <i>Blood</i> , 2009, 114, 2733-2743.	1.4	336
4	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. <i>Blood</i> , 2018, 131, 2515-2527.	1.4	307
5	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017, 77, 1261-1270.	0.9	210
6	Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. <i>Haematologica</i> , 2017, 102, 865-873.	3.5	206
7	Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. <i>Blood</i> , 2009, 114, 5024-5033.	1.4	165
8	Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?. <i>Blood</i> , 2011, 118, 5084-5095.	1.4	163
9	Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. <i>Blood</i> , 2013, 122, 3863-3870.	1.4	153
10	Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. <i>Clinical Therapeutics</i> , 2008, 30, 1956-1975.	2.5	147
11	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3264-3274.	1.6	146
12	Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 89-97.	2.0	130
13	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. <i>HemaSphere</i> , 2021, 5, e646.	2.7	128
14	Enterococcal Bacteremia Is Associated With Increased Risk of Mortality in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2012, 55, 764-770.	5.8	124
15	Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. <i>Blood</i> , 2011, 118, 3096-3106.	1.4	115
16	Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. <i>Leukemia Research</i> , 2011, 35, 1143-1152.	0.8	111
17	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , 2020, 10, 10743-10768.	10.0	107
18	Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival. <i>Bone Marrow Transplantation</i> , 2015, 50, 1432-1437.	2.4	92

#	ARTICLE	IF	CITATIONS
19	Human Herpesvirus 6 Infection after Hematopoietic Cell Transplantation: Is Routine Surveillance Necessary?. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1562-1568.	2.0	87
20	Similar Overall Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning for Older Patients with Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1355-1360.	2.0	81
21	Alternative Donor Transplantation for Older Patients with Acute Myeloid Leukemia in First Complete Remission: A Center for International Blood and Marrow Transplant Research-Eurocord Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 816-822.	2.0	80
22	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
23	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. <i>Leukemia</i> , 2019, 33, 2599-2609.	7.2	76
24	Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. <i>Cancer</i> , 2017, 123, 1828-1838.	4.1	73
25	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.	2.0	71
26	What Is the Optimum Number of CD34+Peripheral Blood Stem Cells for an Autologous Transplant?. <i>Stem Cells and Development</i> , 2004, 13, 598-606.	2.1	70
27	Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells. <i>Clinical Cancer Research</i> , 2008, 14, 6106-6115.	7.0	69
28	Human Parainfluenza Virus Infection after Hematopoietic Stem Cell Transplantation: Risk Factors, Management, Mortality, and Changes Over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1580-1588.	2.0	68
29	To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. <i>Bone Marrow Transplantation</i> , 2013, 48, 1497-1505.	2.4	68
30	Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KITD816V. <i>Leukemia Research</i> , 2009, 33, 735-741.	0.8	66
31	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	1.6	61
32	Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies. <i>Clinical Cancer Research</i> , 2015, 21, 1267-1272.	7.0	60
33	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , 2016, 101, 1133-1143.	3.5	60
34	Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 669-675.	2.0	54
35	Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy. <i>American Journal of Hematology</i> , 2014, 89, 1121-1131.	4.1	51
36	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1254-1265.	2.4	47

#	ARTICLE	IF	CITATIONS
37	Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. <i>Blood</i> , 2010, 116, 5306-5315.	1.4	46
38	Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 487-492.	2.0	44
39	Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 480-486.	2.0	43
40	Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1819-1827.	2.0	43
41	COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter. <i>Leukemia</i> , 2020, 34, 2809-2812.	7.2	43
42	A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: A focus on the incidence of graft-vs.-host disease and relapse. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 28-35.	2.0	42
43	Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia: Similar Outcomes Regardless of Donor Type. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 357-363.	2.0	41
44	Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 744-751.	2.0	41
45	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 767-775.	2.0	41
46	Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1771-1779.	5.8	41
47	Dose Escalation of Total Marrow Irradiation in High-Risk Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1110-1116.	2.0	40
48	Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 1029-1035.	2.4	35
49	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.	5.2	35
50	Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). <i>Blood</i> , 2016, 128, 1069-1069.	1.4	35
51	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1999-2012.e6.	3.8	35
52	Interaction of Sickle Cell Trait with Hereditary Spherocytosis: Splenic Infarcts and Sequestration. <i>Acta Haematologica</i> , 2003, 109, 46-49.	1.4	33
53	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
54	Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia. <i>Current Opinion in Hematology</i> , 2015, 22, 85-91.	2.5	32

#	ARTICLE	IF	CITATIONS
55	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404.	7.1	32
56	Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 795-804.	2.0	31
57	Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 333-342.	2.0	30
58	Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. <i>Bone Marrow Transplantation</i> , 2013, 48, 1415-1420.	2.4	29
59	Plasmablastic lymphoma: CNS involvement, coexistence of other malignancies, possible viral etiology, and dismal outcome. <i>Annals of Hematology</i> , 2009, 88, 351-358.	1.8	28
60	Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged $\geq 70$ Years. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 390-393.	2.0	28
61	Allogeneic Hematopoietic Cell Transplantation in First Remission Abrogates Poor Outcomes Associated with High-Risk Pediatric Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1021-1025.	2.0	27
62	Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2454-2460.	2.0	27
63	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1056-1064.	2.0	26
64	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021, 5, 2481-2489.	5.2	25
65	Eosinophilic Fasciitis after Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature. <i>Leukemia and Lymphoma</i> , 2004, 45, 1707-1709.	1.3	24
66	Resistant Microascus cirrosus pneumonia can be treated with a combination of surgery, multiple anti-fungal agents and a growth factor. <i>Mycopathologia</i> , 2006, 162, 299-302.	3.1	24
67	Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. <i>Blood Advances</i> , 2018, 2, 1580-1584.	5.2	24
68	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
69	Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. <i>Transplant Infectious Disease</i> , 2019, 21, e13145.	1.7	22
70	Acute leukemia with PICALM-MLL10 fusion gene: diagnostic and treatment struggle. <i>Cancer Genetics and Cytogenetics</i> , 2010, 202, 129-132.	1.0	21
71	Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect. <i>Haematologica</i> , 2014, 99, e222-e224.	3.5	21
72	Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis. <i>Leukemia</i> , 2017, 31, 1408-1414.	7.2	21

#	ARTICLE	IF	CITATIONS
73	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
74	Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor. <i>Blood Advances</i> , 2020, 4, 1284-1295.	5.2	21
75	Multiple Myeloma Associated with Lactic Acidosis. <i>Leukemia and Lymphoma</i> , 2002, 43, 2395-2397.	1.3	20
76	Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics. <i>Haematologica</i> , 2018, 103, 2109-2115.	3.5	20
77	Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation. <i>Cancer</i> , 2008, 114, 333-341.	4.1	19
78	Monosomal Karyotype at the Time of Diagnosis or Transplantation Predicts Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 866-872.	2.0	19
79	Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2018, 97, 1027-1039.	1.8	19
80	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1354-1360.	2.4	19
81	Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study. <i>Blood</i> , 2015, 126, 321-321.	1.4	19
82	Importance of donor ethnicity/race matching in unrelated adult and cord blood allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2014, 55, 358-364.	1.3	18
83	Abstract CT184: Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3 mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial. <i>Cancer Research</i> , 2019, 79, CT184-CT184.	0.9	18
84	Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 911-917.	2.4	18
85	History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission. <i>American Journal of Hematology</i> , 2017, 92, 1032-1036.	4.1	17
86	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (CBF-TJ ETQ00 0 0 rgBT /Overlo	2.8	17
87	Infectious Complications in Patients Receiving Mobilization Chemotherapy for Autologous Peripheral Blood Stem Cell Collection. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2003, 12, 155-160.	1.8	16
88	Acute Myelogenous Leukemia Patients Are at Low Risk for Invasive Fungal Infections after High-Dose Cytarabine Consolidations and Thus Do Not Require Prophylaxis. <i>Acta Haematologica</i> , 2010, 124, 206-213.	1.4	16
89	Response of complex immune-mediated thrombocytopenia to romiplostim in the setting of allogeneic stem cell transplantation for chronic myelogenous leukemia. <i>European Journal of Haematology</i> , 2012, 89, 361-364.	2.2	16
90	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 971-979.	2.0	16



#	ARTICLE	IF	CITATIONS
91	Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation. <i>Blood Advances</i> , 2019, 3, 230-236.	5.2	15
92	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. <i>Blood Advances</i> , 2020, 4, 2084-2094.	5.2	14
93	Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 617.e1-617.e7.	1.2	14
94	Relapse Prediction Post Allogeneic Hematopoietic Cell Transplant for Myelodysplastic Syndromes Is Not Improved with Use of the More Stringent Blast Percentage Categories in the Revised International Prognostic Scoring System. <i>Blood</i> , 2012, 120, 2011-2011.	1.4	14
95	Laparoscopic Appendectomy in a Patient with Acute Myelogenous Leukemia with Neutropenia. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2007, 17, 213-215.	1.0	13
96	Heat Shock Protein 90 Inhibition Depletes TrkA Levels and Signaling in Human Acute Leukemia Cells. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2232-2242.	4.1	13
97	Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. <i>Blood Advances</i> , 2019, 3, 2525-2536.	5.2	13
98	Plasmablastic lymphoma with small lymphocytic lymphoma: Clinico-pathologic features, and review of the literature. <i>Leukemia and Lymphoma</i> , 2008, 49, 1999-2002.	1.3	12
99	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 552-558.	2.0	12
100	Complications of Stem Cell Transplantation that Affect Infections in Stem Cell Transplant Recipients, with Analogies to Patients with Hematologic Malignancies. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 331-359.	5.1	12
101	Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD <sup>+</sup> positive acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 3709-3712.	5.2	12
102	Investigational drugs targeting FLT3 for leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1445-1456.	4.1	11
103	Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, E66-E68.	4.1	11
104	Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient. <i>Leukemia Research</i> , 2010, 34, 954-957.	0.8	10
105	Bosutinib, a <i>src</i> family tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis. <i>American Journal of Hematology</i> , 2015, 90, E74.	4.1	10
106	Effectiveness of dasatinib in accelerated-phase chronic myeloid leukemia with p190 BCR-ABL1 and a second Philadelphia chromosome. <i>Cancer Genetics</i> , 2014, 207, 109-110.	0.4	9
107	Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients. <i>American Journal of Hematology</i> , 2017, 92, E529-E533.	4.1	9
108	Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, e20-e25.	2.0	9

#	ARTICLE	IF	CITATIONS
109	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 56-62.	2.0	9
110	Decitabine as a bridge therapy to a MUD transplant in relapsed AML postautologous stem cell transplantation. <i>American Journal of Hematology</i> , 2008, 83, 825-827.	4.1	8
111	Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib. <i>Leukemia Research</i> , 2012, 36, e131-e132.	0.8	8
112	Resolution of osteosclerosis after alloHCT in systemic mastocytosis. <i>Blood</i> , 2016, 127, 1836-1836.	1.4	8
113	Early <i>Clostridioides difficile</i> infection characterizations, risks, and outcomes in allogeneic hematopoietic stem cell and solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2022, 24, e13720.	1.7	8
114	Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia. <i>Cancer Management and Research</i> , 0, , 65.	1.9	7
115	Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?. <i>American Journal of Hematology</i> , 2013, 88, 533-534.	4.1	7
116	Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor. <i>Thorax</i> , 2015, 70, 701-704.	5.6	7
117	Dasatinib-induced immunosuppression and recurrent respiratory tract infections. <i>Leukemia and Lymphoma</i> , 2015, 56, 2484-2485.	1.3	7
118	Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for veno-occlusive disease?. <i>European Journal of Haematology</i> , 2016, 96, 655-657.	2.2	7
119	Spontaneous complete resolution of pneumomediastinum and pneumatosis intestinalis caused by acute GVHD. <i>American Journal of Hematology</i> , 2016, 91, 749-750.	4.1	7
120	Novel disease burden assessment predicts allogeneic transplantation outcomes in myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2016, 51, 199-204.	2.4	7
121	Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1485-1490.	2.0	7
122	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 945-955.	2.0	7
123	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820.	1.3	7
124	The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1747-1756.	2.0	7
125	Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology. <i>Blood Reviews</i> , 2021, 45, 100693.	5.7	7
126	Relapsed acute myelogenous leukemia occurring after 18 years with recurrent novel chromosomal abnormality t(18;22)(q23;q11.2). <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 135-138.	1.0	6



#	ARTICLE	IF	CITATIONS
127	Fatal <i>Aspergillus fumigatus</i> and <i>Candida glabrata</i> infections with posaconazole prophylaxis after stem cell transplantation. <i>International Journal of Antimicrobial Agents</i> , 2008, 32, 365-366.	2.5	6
128	Human Herpesvirus 6 is Associated with Status Epilepticus and Hyponatremia after Umbilical Cord Blood Transplantation. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2014, 25, 170-172.	1.9	6
129	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e19-e25.	1.3	6
130	Anti-AML Activity of Combined Epigenetic Therapy with Novel DNMT1 Inhibitors SGI-110 or SGI-1036 and Histone Deacetylase Inhibitor Panobinostat.. <i>Blood</i> , 2008, 112, 3355-3355.	1.4	6
131	Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study. <i>Turkish Journal of Haematology</i> , 2017, 34, 16-26.	0.5	6
132	Potential Pitfalls In Quantitative Real-Time PCR for Molecular Monitoring of BCR-ABL In the Management of CML.. <i>Blood</i> , 2010, 116, 1228-1228.	1.4	6
133	Immunosuppressive treatment in patient with pure red cell aplasia associated with chronic myelomonocytic leukemia: harm or benefit?. <i>International Journal of Hematology</i> , 2009, 90, 597-600.	1.6	5
134	Lethal small bowel necrosis due to aspergillosis during acute promyelocytic leukemia induction. <i>American Journal of Hematology</i> , 2013, 88, 329-332.	4.1	5
135	Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD. <i>Haematologica</i> , 2016, 101, e348-e351.	3.5	5
136	Anaplastic mast cell sarcoma: a unique pathologic entity in mastocytosis. <i>Leukemia and Lymphoma</i> , 2017, 58, 1515-1517.	1.3	5
137	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 581-586.	2.0	5
138	Information Needs for Treatment Decision-making of Hematopoietic Cell Transplant Patients 65 Years or Older and Caregivers. <i>Journal of Cancer Education</i> , 2020, 35, 651-660.	1.3	5
139	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	5.2	5
140	Association of breast cancer and immune thrombocytopenic purpura. <i>Southern Medical Journal</i> , 2002, 95, 1335-7.	0.7	5
141	Acute splenic complications and implications of splenectomy in hemoglobin SC disease. <i>European Journal of Haematology</i> , 2009, 83, 258-260.	2.2	4
142	Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: A case review. <i>American Journal of Hematology</i> , 2012, 87, 191-193.	4.1	4
143	Patients With a History of Chemotherapy and Isolated del(20q) With Minimal Myelodysplasia Have an Indolent Course. <i>American Journal of Clinical Pathology</i> , 2016, 145, 459-466.	0.7	4
144	Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation. <i>Cancer</i> , 2021, 127, 4339-4347.	4.1	4

#	ARTICLE	IF	CITATIONS
145	Phase 1 Clinical Investigation of Human Myeloid Progenitor Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 2268-2268.	1.4	4
146	Impact of Frailty on Hematopoietic Cell on Early Transplant Outcomes in Older Recipients. <i>Blood</i> , 2015, 126, 388-388.	1.4	4
147	Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd. <i>Blood</i> , 2021, 138, 261-261.	1.4	4
148	Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab. <i>Leukemia and Lymphoma</i> , 2013, 54, 174-176.	1.3	3
149	Diabetes insipidus in myelodysplastic syndrome: what we learnt from a case regarding its diagnosis, pathophysiology and management. <i>Leukemia and Lymphoma</i> , 2015, 56, 1134-1136.	1.3	3
150	Impending relapse of myelodysplastic syndrome after allogeneic transplant is difficult to diagnose and requires a multi-modal approach. <i>BMC Clinical Pathology</i> , 2017, 17, 28.	1.8	3
151	Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual diseaseâ€negative first complete remission. <i>American Journal of Hematology</i> , 2018, 93, E381-E383.	4.1	3
152	Sarcoid-like Histiocytic Proliferations in Patients With Lymphoma Can Be FDG-avid Concerning for Refractory or Recurrent Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e597-e601.	0.4	3
153	LBH589 (panobinostat): A Potential Novel Anti-Switching Therapy.. <i>Blood</i> , 2009, 114, 2568-2568.	1.4	3
154	Similar Outcome Between Siblings, Unrelated Donors and Cord Blood After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation for Patients Older Than 50 Years with Acute Myeloid Leukemia in Complete Remission. <i>Blood</i> , 2012, 120, 1985-1985.	1.4	3
155	Similar Survival after Umbilical Cord Blood (UCB) and HLA-Matched Adult Donor Transplantation By Disease Risk Index (DRI) Assignment. <i>Blood</i> , 2015, 126, 4375-4375.	1.4	3
156	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	1.2	3
157	How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. <i>American Journal of Hematology</i> , 2013, 88, 826-827.	4.1	2
158	A patient with skin lesions, osteosclerosis and hepatosplenomegaly. <i>British Journal of Haematology</i> , 2014, 167, 291-291.	2.5	2
159	Concomitant cutaneous squamous cell carcinoma and chronic lymphocytic leukemia in a patient: The utility of <sup>18</sup> Fâ€FDG PET/CT in differentiation of nodal metastasis. <i>American Journal of Hematology</i> , 2018, 93, 597-598.	4.1	2
160	A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2352-2359.	1.3	2
161	Genomics of clonal evolution in a case of essential thrombocythemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 497-500.	1.3	2
162	Importance of conditioning regimen intensity, MRD positivity, and KIR ligand mismatch in UCB transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 97-100.	2.4	2

#	ARTICLE	IF	CITATIONS
163	Trispecific Killer Engager CD16xIL15xCD33 Enhances Alloreactivity of NK Cells Against Aberrant Mast Cells of Patients with Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S174-S175.	2.0	2
164	The challenges of treating aspergillus abdominal aneurysm after hematopoietic cell transplant: Rapid voriconazole metabolizer. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 703-705.	0.9	2
165	Calcineurin-inhibitor induced pain syndrome after stem cell transplant. <i>Leukemia and Lymphoma</i> , 2020, 61, 2230-2233.	1.3	2
166	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study. <i>Blood</i> , 2018, 132, 71-71.	1.4	2
167	Primary Low-Grade Lymphomas of the Intestine. <i>Journal of Clinical Oncology</i> , 1999, 17, 3682-3684.	1.6	1
168	Rituximab Provides Durable Remission in a Patient with Refractory Aggressive Diffuse B-cell Lymphoma Failing Salvage Chemotherapy. <i>Leukemia and Lymphoma</i> , 2002, 43, 2235-2236.	1.3	1
169	Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient. <i>American Journal of Hematology</i> , 2009, 84, 386-387.	4.1	1
170	Nasal GVHD. <i>Bone Marrow Transplantation</i> , 2015, 50, 148-149.	2.4	1
171	Is Haploidentical HCT Better Than? A Wrong Question for Future Studies. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e303-e304.	2.0	1
172	In Vitro Closure Times (PFA-100) Are Different Between Peritoneal Dialysis and Hemodialysis. <i>Hamostaseologie</i> , 2020, 40, 671-678.	1.9	1
173	Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2020, 61, 2008-2011.	1.3	1
174	Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. <i>Blood Advances</i> , 2020, 4, 2317-2324.	5.2	1
175	Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome. <i>Leukemia Research</i> , 2020, 95, 106404.	0.8	1
176	Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation. <i>European Journal of Haematology</i> , 2021, 106, 205-212.	2.2	1
177	Lack of Clustering of SCD Complications Into Two Distinct Subphenotypes In An Adult Patient Population.. <i>Blood</i> , 2010, 116, 1643-1643.	1.4	1
178	HCT related toxicities and mortality in frail recipients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18534-e18534.	1.6	1
179	Hepatic Manifestations of Systemic Mastocytosis (SM). <i>American Journal of Gastroenterology</i> , 2010, 105, S294.	0.4	1
180	Outcomes of COVID-19 Infection in Patients with Hematologic Malignancies. <i>Blood</i> , 2020, 136, 20-21.	1.4	1

#	ARTICLE	IF	CITATIONS
181	Transplantation provides superior survival high risk myeloid malignancies in older patients. <i>Leukemia and Lymphoma</i> , 2022, 63, 2494-2498.	1.3	1
182	Liver Fibrosis and its Response to Avapritinib in 2 Patients with Systemic Mastocytosis. <i>Blood Advances</i> , 0, , .	5.2	1
183	A Serious Complication of Allogeneic Stem Cell Transplantation: Relapsing <i>Pseudomonas aeruginosa</i> Panniculitis. <i>Clinical Medicine Oncology</i> , 2007, 1, 117955490700100.	0.3	0
184	Amyloidosis, Evans syndrome and management options of lymphoplasmacytic lymphoma. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 42-46.	3.0	0
185	Similar Survival in Patients with Acute Myeloid Leukemia Relapsing After Matched Related Donor and Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S113.	2.0	0
186	Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison Among Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S92.	2.0	0
187	New Models of Therapy: When Acute Leukemia Becomes Chronic. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1856-1857.	2.0	0
188	<i>Clostridium difficile</i> Infection Among Allogeneic Hematopoietic Stem Cell and Solid Organ Transplant Recipients: Differences in Rates and Outcomes. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
189	Encapsulated relapsed FLT3+AML (myeloid sarcoma) and <i>thyroid</i> cell adenoma presenting in composite: Unlikely partners. <i>American Journal of Hematology</i> , 2016, 91, E505-E506.	4.1	0
190	Similar Invasive Fungal Infection Rates and Survival after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Bone Marrow or Peripheral Blood Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S174-S175.	2.0	0
191	Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state. <i>American Journal of Hematology</i> , 2017, 92, E549-E552.	4.1	0
192	Time-to-Event Ratio to Predict Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1804-1808.	2.0	0
193	Weight-Based Mycophenolate Mofetil Dosing Predicts Acute Gvhd and Relapse after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S291.	2.0	0
194	Improved Mortality Prognostication for Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results From a Virtual Pediatric Systems (VPS) and Center for International Blood and Marrow Transplant Research (CIBMTR) Database Merger. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S117-S119.	2.0	0
195	Necessity for treatment of steroid refractory severe GIT GVHD: patience of providers. <i>Bone Marrow Transplantation</i> , 2020, 55, 833-835.	2.4	0
196	DLBCL After Allogeneic HCT in a Patient With Transformed DLBCL: Does It Matter Whether Relapse or PTLD?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 264-266.	0.4	0
197	Biosimilar infliximab administration for the management of acute graft-versus-host disease. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 2047-2051.	0.9	0
198	Presumed mast cell choroidal infiltrate in aggressive systemic mastocytosis. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 18, 100614.	0.7	0

#	ARTICLE	IF	CITATIONS
199	Human Herpesvirus-6 Infection and Calcineurin Inhibitor Pain Syndrome Interaction after Umbilical Cord Blood Transplant. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 439-440.	1.2	0
200	Spleen Related Complications and Implications of Splenectomy in Patients with Hemoglobin SC Disease.. <i>Blood</i> , 2007, 110, 3798-3798.	1.4	0
201	Synergistic Pre-Clinical Activity of Combined Epigenetic Therapy with the Novel Histone Methyltransferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat against Human AML Cells.. <i>Blood</i> , 2008, 112, 3356-3356.	1.4	0
202	Allogeneic Hematopoietic Stem Cell Transplantation Overcomes the Adverse Prognostic Impact of Minimal Residual Disease in Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 2027-2027.	1.4	0
203	Are IPSS-R and IPSS Cytogenetic Risk Stratification Informative At the Time of Allogeneic Hematopoietic Cell Transplantation?. <i>Blood</i> , 2012, 120, 1400-1400.	1.4	0
204	Positive Positron Emission Tomography (PET) Scan in Non-Hodgkin Lymphoma Pre-Transplant Had No Impact On Relapse and Survival After Allogeneic Transplantation. <i>Blood</i> , 2012, 120, 1999-1999.	1.4	0
205	Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. <i>Blood</i> , 2013, 122, 2145-2145.	1.4	0
206	Alternative Donor Hematopoietic Transplantation For Patients Older Than 50 Years With AML In First Complete Remission: Unrelated Donor and Umbilical Cord Blood Transplantation Outcomes. <i>Blood</i> , 2013, 122, 302-302.	1.4	0
207	The Effect of Measurable Residual Disease at the Time of Allogeneic Hematopoietic Cell Transplantation on Outcomes in Patients with Acute Myeloid Leukemia: A Meta-Analysis. <i>Blood</i> , 2016, 128, 2842-2842.	1.4	0
208	Umbilical Cord Blood Transplantation and Delay Engraftment Are Associated with Increased Risks of Diffuse Alveolar Hemorrhage. <i>Blood</i> , 2016, 128, 2222-2222.	1.4	0
209	Allogeneic Hematopoietic Cell Transplantation for Elderly Patients: Prognosis Determined By Disease Risk Index. <i>Blood</i> , 2016, 128, 2305-2305.	1.4	0
210	UCB HCT in FLT3+ AML. <i>Oncotarget</i> , 2017, 8, 81733-81734.	1.8	0
211	Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study. <i>Blood</i> , 2018, 132, 2170-2170.	1.4	0
212	Management of Hematologic Disease in Mastocytosis. , 2020, , 231-255.		0
213	The Incidence and Impact of Clostridioides Difficile Infection (CDI) on Outcomes after Allogeneic Hematopoietic Cell Transplant (alloHCT) - a CIBMTR Study. <i>Blood</i> , 2021, 138, 2894-2894.	1.4	0
214	The Impact of Non-Clinical Factors in Clinical Trial Enrollments of Patients with Hematologic Malignancies. <i>Blood</i> , 2021, 138, 1914-1914.	1.4	0
215	Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. <i>Blood</i> , 2020, 136, 7-8.	1.4	0